Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.48 |
| ▸ | TACR1 | P25103 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL345549 | 0.98 | MRGPRX4 (0.47) | MRGPRX4TACR1ALDH1A1LSSSERPINE1 | |
| SCHEMBL6121602 | 0.98 | MRGPRX4 (0.47) | MRGPRX4TACR1ALDH1A1LSSSERPINE1 | |
| SCHEMBL9928607 | 0.87 | RXRA (0.49) | TACR1ALDH1A1LSSSERPINE1CES2 | |
| Lithium Ion SCHEMBL6121595 | 0.84 | LSS (0.45) | MRGPRX4TACR1ALDH1A1LSSSERPINE1 | |
| SCHEMBL9927096 | 0.83 | TACR1 (0.45) | TACR1LSSSERPINE1CES2 | |
| SCHEMBL1869219 | 0.82 | ALDH1A1 (0.60) | ALDH1A1 | |
| SCHEMBL17897037 | 0.81 | MRGPRX4 (0.51) | MRGPRX4ALDH1A1CES2RXRARXRB | |
| SCHEMBL3005488 | 0.81 | CACNA1G (0.49) | MRGPRX4TACR1SERPINE1 | |
| SCHEMBL13451382 | 0.80 | TACR1 (0.49) | TACR1ALDH1A1LSSSERPINE1 | |
| SCHEMBL27761970 | 0.80 | RXRA (0.53) | MRGPRX4CES2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| CN-108467369-A | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | 诺华股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| CN-105143209-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2018-03-13 | — | — | CN | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MRGPRX4 3391/4885TACR1 2364/4885ALDH1A1 559/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MRGPRX4 3664/4885TACR1 4788/4885ALDH1A1 2049/4885 |
| US-20100197924-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | MRGPRX4 3622/4885TACR1 2509/4885ALDH1A1 3084/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | MRGPRX4 3261/4885TACR1 2273/4885ALDH1A1 487/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | MRGPRX4 3038/4885TACR1 4666/4885ALDH1A1 1592/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | MRGPRX4 3038/4885TACR1 4666/4885ALDH1A1 1592/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | MRGPRX4 3038/4885TACR1 4666/4885ALDH1A1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.